This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

HOPE study in diabetics

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The Heart Outcomes Prevention Evaluation (HOPE) study of diabetic patients investigated the role of the ACE inhibitor ramipril in diabetic patients with a cardiovascular risk factor.

3577 patients with diabetes were recruited as part of the HOPE study.

The analysis of the diabetic subgroup of the main trial was planned in advance.

Patients were recruited if they:

  • were diabetic
  • were 55 years or older
  • had a cardiovascular risk factor
  • did not satisfy the exclusion criteria

The primary outcome was the combination of:

  • myocardial infarction
  • stroke
  • cardiovascular death A main outcome was overt nephropathy.

Patients were randomised in a two-by-two factorial manner to:

  • ramipril 10 mg daily or placebo
  • vitamin E or placebo

There were significant benefits for the following end-points in those patients randomised to ramipril:

  • combined primary outcome
  • MI
  • stroke
  • cardiovascular death
  • total mortality
  • revascularisation
  • overt nephropathy


  • (1) HOPE Study Investigators (2000). Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet, 355, 253-59.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.